VascVersa secures Launchpad NI funding

VascVersa are pleased to announce their success in securing Launchpad NI funding. This funding will allow VascVersa to assess the suitability of their novel cell therapy Angicyte® for indications outside of diabetic foot ulcers and other chronic wounds. Partnering with MediNect Optho, VascVersa will be investigating the potential of Angicyte® to treat ischaemic retinopathies.